ABSTRACT
Introduction The 2018 Farm Bill unintentionally allowed the proliferation of derived intoxicating cannabis vape products (DICVPs), raising concerns about associated health risks. To inform public health prevention efforts, this study analyzed the product attributes and marketing features of DICVPs in an online retail environment.
Methods In 2023, we extracted information on product attributes and descriptions of 490 DICVPs from two online retail websites with high web traffic. In 2024, two trained coders thematically coded product descriptions for their product characteristics and marketing features.
Results Overall, 95 unique brands and 26 unique intoxicating cannabinoids were identified. The most frequent marketing features were overall vape product design and use (99.0%), including vaping satisfaction, discreetness, convenience, and use instructions. Regulation and compliance messages (91.6%) were also prevalent, including lab testing for additives and/or chemicals, health warnings, hemp-derived labels, references to the 2018 Farm Bill, and FDA approval statements. Other prominent themes included: flavor and sensation claims (79.6%, i.e., flavor variety, fruit flavors); psychoactive effect claims (43.3%, e.g., potency or expected user experience); product quality claims (38.4%, e.g., “quality,” “natural,” “purity”); and other positive effect claims (33.9%, e.g., mood enhancement, relaxation).
Discussion The DICVP online marketplace is highly fragmented with a variety of brands and intoxicating compounds. Common marketing strategies promoting appealing flavors and positive vaping experiences may increase product use interest among young people. Features related to product legality and quality may reduce perceived barriers and risks of using products. Continuous monitoring of the DICVP marketplace is needed to inform policymaking.
Competing Interest Statement
Dr. Kong has served as a paid expert consultant in litigation against the tobacco industry.
Funding Statement
Dr. LoParco is supported by the National Institute on Drug Abuse (F32DA060612).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding source: Dr. LoParco is supported by the National Institute on Drug Abuse (F32DA060612). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclosure: Dr. Kong has served as a paid expert consultant in litigation against the tobacco industry.
Data Availability
All data produced are available on the websites
